Market Overview

UPDATE: Bank of America Upgrades Ariad Pharmaceuticals to Buy on Risk/Reward

Related ARIA
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial

Bank of America raised its rating on Ariad Pharmaceuticals (NASDAQ: ARIA) from Neutral to Buy and increased its price objective from $20 to $26.

Bank of America noted, "Despite ARIA shares +80% YTD performance, we are upgrading from Neutral to Buy based on the favorable risk/reward profile on near term data for ‘113 in lung cancer and subsequent Phase 2 expansion results, as well as our less conservative view of valuation for lead drug PON. While our new PO of $26 (up from $20) does not reflect a large premium to the current stock price, we see 15-70% upside to shares following upcoming lung cancer data (Sept 28-30). The key near term risk to ARIA is negative results for ‘113 ($6/sh of our current valuation), which seems unlikely given trial progress and management's enthusiasm."

Ariad Pharmaceuticals closed at $22.01 on Friday.

Latest Ratings for ARIA

Jan 2016BarclaysInitiates Coverage onUnderweight
Dec 2014Credit SuisseDowngradesNeutralUnderperform
Aug 2014CitigroupMaintainsSell

View More Analyst Ratings for ARIA
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ARIA)

View Comments and Join the Discussion!

Get Benzinga's Newsletters